RW Nesto, D Bell, RO Bonow, V Fonseca, SM Grundy, … - Circulation, 2003 - Am Heart Assoc These beneficial effects of TZDs on glycemia and cardiovascular risk factors have made them
attractive agents in patients with type 2 diabetes who are at high risk for CVD. There is a growing
recognition, however, that edema can occur in patients treated with either drug. Because ... Cited by 575 - Related articles - BL Direct - All 17 versions
- ►ahajournals.org SC Benson, HA Pershadsingh, CI Ho, A Chittiboyina, P … - Hypertension, 2004 - Am Heart Assoc The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes
that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood
pressure. In humans, mutations in the peroxisome proliferator–activated receptor- (PPAR ... Cited by 432 - Related articles - BL Direct - All 10 versions
- ►jhsph.edu [PDF] SE Nissen, K Wolski, EJ Topol - Jama, 2005 - Am Med Assoc Context Peroxisome proliferator–activated receptors (PPARs) are nuclear transcription factors
that modulate gene expression. Therapeutic agents targeting 2 distinct families of PPARs ( and
) have been introduced in the United States. The first dual-PPAR agonist, muraglitazar, ... Cited by 261 - Related articles - BL Direct - All 9 versions
- ►ahajournals.org FA Masoudi, SE Inzucchi, Y Wang, EP Havranek, JAM … - Circulation, 2005 - Am Heart Assoc Methods and Results— We conducted a retrospective cohort study of 16 417 Medicare beneficiaries
with diabetes discharged after hospitalization with the principal discharge diagnosis of heart
failure. The association between antidiabetic drug prescriptions and outcomes was ... Cited by 195 - Related articles - All 10 versions
- ►infodiabetes.it [PDF] LL Lipscombe, T Gomes, LE Levesque, JE Hux, DN … - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Context Thiazolidinediones (TZDs), used to treat ... Cited by 118 - Related articles - BL Direct - All 9 versions
- ►oxfordjournals.org MA Peraza, AD Burdick, HE Marin, FJ Gonzalez, … - Toxicological …, 2006 - Soc Toxicology Peroxisome proliferator-activated receptors (PPARs) are ligand activated transcription factors
that modulate target gene expression in response to endogenous and exogenous ligands. Ligands
for the PPARs have been widely developed for the treatment of various diseases ... Cited by 88 - Related articles - All 6 versions
- ►onlinejacc.org HJ Dargie, PR Hildebrandt, GAJ Riegger, JJV … - Journal of the American …, 2007 - Elsevier This study investigated the effects of rosiglitazone (RSG) on left ventricular ejection fraction
(LVEF) in subjects with type 2 diabetes (T2DM) and pre-existing chronic heart failure (CHF)
(New York Heart Association [NYHA] functional class I to II). ... Fluid retention is an ... Cited by 88 - Related articles - BL Direct - All 13 versions
- ►nih.gov L Michalik, W Wahli - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig Tissue damage resulting from chemical, mechanical, and biological injury, or from interrupted
blood flow and reperfusion, is often life threatening. The subsequent tissue response involves
an intricate series of events including inflammation, oxidative stress, immune cell ... Cited by 82 - Related articles - BL Direct - All 10 versions
AJ Karter, AT Ahmed, J Liu, HH Moffet, MM … - Diabetic …, 2005 - interscience.wiley.com Methods A cohort study of all patients in the Kaiser Permanente Medical Care Program with Type
2 diabetes (Kaiser Permanente Northern California Diabetes Registry) who initiated any diabetes
pharmacotherapy (n = 23 440) between October 1999 and November 2001. Only patients ... Cited by 69 - Related articles - BL Direct - All 4 versions
HA Pershadsingh - eid, 2004 - informahealthcare.com The discovery that the insulin-sensitising thiazolidinediones (TZDs), specific peroxisome
proliferator-activated receptor-γ (PPARγ) agonists, have antipro- liferative, anti-inflammatory
and immunomodulatory effects has led to the evaluation of their potential use in the ... Cited by 69 - Related articles - All 5 versions
